Annual CFI
-$73.04 M
-$103.25 M-341.76%
December 1, 2023
Summary
- As of February 7, 2025, ORMP annual cash flow from investing activities is -$73.04 million, with the most recent change of -$103.25 million (-341.76%) on December 1, 2023.
- During the last 3 years, ORMP annual CFI has fallen by -$70.63 million (-2936.92%).
- ORMP annual CFI is now -341.76% below its all-time high of $30.21 million, reached on December 31, 2022.
Performance
ORMP Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$34.26 M
-$128.91 M-136.19%
September 1, 2024
Summary
- As of February 7, 2025, ORMP quarterly cash flow from investing activities is -$34.26 million, with the most recent change of -$128.91 million (-136.19%) on September 1, 2024.
- Over the past year, ORMP quarterly CFI has dropped by -$64.26 million (-214.21%).
- ORMP quarterly CFI is now -136.19% below its all-time high of $94.66 million, reached on June 1, 2024.
Performance
ORMP Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
$120.39 M
+$40.86 M+51.38%
September 1, 2024
Summary
- As of February 7, 2025, ORMP TTM cash flow from investing activities is $120.39 million, with the most recent change of +$40.86 million (+51.38%) on September 1, 2024.
- Over the past year, ORMP TTM CFI has increased by +$193.43 million (+264.83%).
- ORMP TTM CFI is now at all-time high.
Performance
ORMP TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
ORMP Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -341.8% | -214.2% | +264.8% |
| 3 y3 years | -2936.9% | -430.6% | +209.1% |
| 5 y5 years | -748.7% | -1399.2% | +985.7% |
ORMP Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -341.8% | +26.4% | -136.2% | +65.4% | at high | +197.1% |
| 5 y | 5-year | -341.8% | +26.4% | -136.2% | +65.4% | at high | +197.1% |
| alltime | all time | -341.8% | +26.4% | -136.2% | +65.4% | at high | +197.1% |
Oramed Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$34.26 M(-136.2%) | $120.39 M(+51.4%) |
| Jun 2024 | - | $94.66 M(+215.5%) | $79.53 M(-366.5%) |
| Mar 2024 | - | $30.00 M(+0.0%) | -$29.84 M(-59.1%) |
| Dec 2023 | -$73.04 M(-341.8%) | $30.00 M(-139.9%) | -$73.04 M(-20.4%) |
| Sep 2023 | - | -$75.12 M(+410.7%) | -$91.78 M(+495.0%) |
| Jun 2023 | - | -$14.71 M(+11.4%) | -$15.42 M(-259.9%) |
| Mar 2023 | - | -$13.20 M(-217.3%) | $9.65 M(-68.1%) |
| Dec 2022 | $30.21 M(-130.4%) | $11.26 M(+816.2%) | $30.21 M(-137.7%) |
| Sep 2022 | - | $1.23 M(-88.1%) | -$80.10 M(-27.4%) |
| Jun 2022 | - | $10.36 M(+40.8%) | -$110.37 M(-2.6%) |
| Mar 2022 | - | $7.36 M(-107.4%) | -$113.34 M(-8.6%) |
| Dec 2021 | -$99.25 M(+317.6%) | - | - |
| Nov 2021 | - | -$99.05 M(+241.0%) | -$124.01 M(+421.8%) |
| Aug 2021 | -$23.76 M(+888.1%) | -$29.05 M(-492.8%) | -$23.76 M(-246.3%) |
| May 2021 | - | $7.39 M(-323.4%) | $16.25 M(-470.5%) |
| Feb 2021 | - | -$3.31 M(-376.1%) | -$4.38 M(-246.2%) |
| Dec 2020 | -$2.40 M(-152.0%) | - | - |
| Nov 2020 | - | $1.20 M(-89.1%) | $3.00 M(-35.1%) |
| Aug 2020 | $4.63 M(-58.9%) | $10.96 M(-182.8%) | $4.63 M(-225.0%) |
| May 2020 | - | -$13.24 M(-424.8%) | -$3.70 M(-127.0%) |
| Feb 2020 | - | $4.08 M(+44.2%) | $13.71 M(+23.7%) |
| Nov 2019 | - | $2.83 M(+7.1%) | $11.09 M(-1.5%) |
| Aug 2019 | $11.26 M(-260.8%) | $2.64 M(-36.9%) | $11.26 M(-683.1%) |
| May 2019 | - | $4.18 M(+188.1%) | -$1.93 M(-12.5%) |
| Feb 2019 | - | $1.45 M(-51.6%) | -$2.21 M(-294.2%) |
| Nov 2018 | - | $3.00 M(-128.4%) | $1.14 M(-116.2%) |
| Aug 2018 | -$7.00 M(-262.8%) | -$10.55 M(-370.6%) | -$7.00 M(-206.7%) |
| May 2018 | - | $3.90 M(-18.7%) | $6.56 M(+23.8%) |
| Feb 2018 | - | $4.79 M(-193.2%) | $5.30 M(+104.5%) |
| Nov 2017 | - | -$5.15 M(-270.7%) | $2.59 M(-39.7%) |
| Aug 2017 | $4.30 M(-126.9%) | $3.01 M(+14.3%) | $4.30 M(-185.7%) |
| May 2017 | - | $2.64 M(+26.4%) | -$5.02 M(-7.3%) |
| Feb 2017 | - | $2.09 M(-160.7%) | -$5.42 M(-73.3%) |
| Nov 2016 | - | -$3.44 M(-45.5%) | -$20.26 M(+26.6%) |
| Aug 2016 | -$16.01 M(+383.4%) | -$6.31 M(-381.4%) | -$16.01 M(+12.9%) |
| May 2016 | - | $2.24 M(-117.6%) | -$14.19 M(+11.0%) |
| Feb 2016 | - | -$12.76 M(-1659.9%) | -$12.78 M(+221.8%) |
| Nov 2015 | - | $818.00 K(-118.2%) | -$3.97 M(+19.9%) |
| Aug 2015 | -$3.31 M | -$4.49 M(-222.9%) | -$3.31 M(-362.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| May 2015 | - | $3.65 M(-192.3%) | $1.26 M(-155.7%) |
| Feb 2015 | - | -$3.95 M(-367.8%) | -$2.27 M(-80.2%) |
| Nov 2014 | - | $1.48 M(+1522.0%) | -$11.45 M(-12.5%) |
| Aug 2014 | -$13.09 M(+186.5%) | $91.00 K(-20.9%) | -$13.09 M(-18.7%) |
| May 2014 | - | $115.00 K(-100.9%) | -$16.10 M(-0.1%) |
| Feb 2014 | - | -$13.13 M(+8006.2%) | -$16.11 M(+210.7%) |
| Nov 2013 | - | -$162.00 K(-94.5%) | -$5.19 M(+13.5%) |
| Aug 2013 | -$4.57 M(-358.3%) | -$2.93 M(-2854.4%) | -$4.57 M(+181.9%) |
| May 2013 | - | $106.20 K(-104.8%) | -$1.62 M(+16.9%) |
| Feb 2013 | - | -$2.20 M(-585.3%) | -$1.39 M(-178.2%) |
| Nov 2012 | - | $454.20 K(+1857.8%) | $1.77 M(+0.3%) |
| Aug 2012 | $1.77 M(-203.9%) | $23.20 K(-93.2%) | $1.77 M(+2.1%) |
| May 2012 | - | $340.20 K(-64.4%) | $1.73 M(+25.5%) |
| Feb 2012 | - | $956.60 K(+113.1%) | $1.38 M(-201.9%) |
| Nov 2011 | - | $448.90 K(-3450.0%) | -$1.35 M(-20.5%) |
| Aug 2011 | -$1.70 M(-289.0%) | -$13.40 K(+16.5%) | -$1.70 M(+32.1%) |
| May 2011 | - | -$11.50 K(-99.4%) | -$1.29 M(+241.9%) |
| Feb 2011 | - | -$1.78 M(-1878.5%) | -$377.30 K(-126.9%) |
| Nov 2010 | - | $100.00 K(-75.0%) | $1.40 M(+55.5%) |
| Aug 2010 | $901.20 K(-47.6%) | $400.10 K(-55.6%) | $901.20 K(-280.3%) |
| May 2010 | - | $901.10 K(>+9900.0%) | -$499.70 K(-64.4%) |
| Feb 2010 | - | $0.00(-100.0%) | -$1.40 M(-535.8%) |
| Nov 2009 | - | -$400.00 K(-60.0%) | $321.80 K(-81.3%) |
| Aug 2009 | $1.72 M(-160.4%) | -$1.00 M(>+9900.0%) | $1.72 M(-6560.2%) |
| May 2009 | - | -$1500.00(-100.1%) | -$26.60 K(-32.7%) |
| Feb 2009 | - | $1.72 M(+73.0%) | -$39.50 K(-97.9%) |
| Nov 2008 | - | $996.60 K(-136.3%) | -$1.84 M(-35.3%) |
| Aug 2008 | -$2.84 M(>+9900.0%) | -$2.75 M(>+9900.0%) | -$2.84 M(+2743.8%) |
| May 2008 | - | -$14.40 K(-81.2%) | -$100.00 K(+16.8%) |
| Feb 2008 | - | -$76.40 K(+961.1%) | -$85.60 K(+830.4%) |
| Nov 2007 | - | -$7200.00(+260.0%) | -$9200.00(+360.0%) |
| Aug 2007 | -$2000.00(<-9900.0%) | -$2000.00(<-9900.0%) | -$2000.00(<-9900.0%) |
| May 2007 | - | $0.00(0.0%) | $0.00(0.0%) |
| Feb 2007 | - | $0.00(0.0%) | $0.00(0.0%) |
| Nov 2006 | - | $0.00(0.0%) | $0.00(0.0%) |
| Aug 2006 | $0.00(0.0%) | $0.00(0.0%) | $0.00(0.0%) |
| May 2006 | - | $0.00(0.0%) | $0.00(0.0%) |
| Feb 2006 | - | $0.00(0.0%) | $0.00(0.0%) |
| Nov 2005 | - | $0.00 | $0.00 |
| Aug 2005 | $0.00 | - | - |
FAQ
- What is Oramed Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals annual CFI year-on-year change?
- What is Oramed Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals quarterly CFI year-on-year change?
- What is Oramed Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals TTM CFI year-on-year change?
What is Oramed Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of ORMP is -$73.04 M
What is the all time high annual CFI for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high annual cash flow from investing activities is $30.21 M
What is Oramed Pharmaceuticals annual CFI year-on-year change?
Over the past year, ORMP annual cash flow from investing activities has changed by -$103.25 M (-341.76%)
What is Oramed Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of ORMP is -$34.26 M
What is the all time high quarterly CFI for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high quarterly cash flow from investing activities is $94.66 M
What is Oramed Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, ORMP quarterly cash flow from investing activities has changed by -$64.26 M (-214.21%)
What is Oramed Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of ORMP is $120.39 M
What is the all time high TTM CFI for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high TTM cash flow from investing activities is $120.39 M
What is Oramed Pharmaceuticals TTM CFI year-on-year change?
Over the past year, ORMP TTM cash flow from investing activities has changed by +$193.43 M (+264.83%)